Roth Capital Partners (Roth) has become aware that there are individuals on WhatsApp and possibly other social media outlets who are falsely impersonating employees or people connected with this firm. Please be aware that any such messages are not authorized by Roth and are apparently being used to perpetrate illegitimate activity. For more information please visit – Here
| Jonathan Aschoff, Ph.D., is a Managing Director, Senior Research Analyst at ROTH, specializing in the biotechnology sector. With over 20 years of experience as a sell-side analyst, he has focused primarily on small and microcap companies within the biotechnology industry. Throughout his career, he has earned several awards in the biotechnology or pharmaceutical sector based on investment return, including recognition from organizations such as The Wall Street Journal, Financial Times, Forbes, Starmine, and Tipranks. Dr. Aschoff earned a B.S. in Biology and a Ph.D. in Microbiology and Molecular Biology from Tufts University. During his Ph.D. studies at Tufts University School of Medicine, his research involved investigating the function of the 3' untranslated avian retroviral genomic mRNA region. |
jaschoff@roth.com
November 2019
Healthcare
B.S.from Tufts University; Ph.D. from Tufts University School of Medicine
Sturzas's Institutional Research; Dain Rauscher Wessels; Friedman Billings Ramsey; Maxim, Brean Capital; National Securitie
Biotechnology No. 3 Master Stock Picker “Best on the Street” Award The Wall Street Journal 2005
Pharmaceuticals No. 1 Master Stock Picker “Best on the Street” Award The Wall Street Journal 2005
Biotechnology No. 1 Stock Picker “Best Brokerage Analysts” Award, Forbes StarMine 2007
Biotechnology No. 2 Master Stock Picker “Best on the Street” Award The Wall Street Journal 2008
Biotechnology No. 2 Stock Picker Analyst Award, FT StarMine 2011
Named as TipRanks No. 1 Analyst across all sector for 2014 No. 1 Analyst across all sector for 2014 TipRanks
